A novel mutation in the Connexin 46 gene causes autosomal dominant congenital cataract with incomplete penetrance

K P Burdon, M G Wirth, D A Mackey, I M Russell-Eggitt, J E Craig, J E Elder, J L Dickinson, M M Sale


Congenital or paediatric cataract is a phenotypically and genetically heterogeneous disorder consisting of lens opacities in early life. Thirteen genes have been described for autosomal dominant congenital cataract (ADCC). These include genes for seven members of the crystallin family,1,2 which are responsible for the refractive index and transparency of the lens, two connexin genes3,4 and major intrinsic protein of the lens (MIP)5 which are involved in the transport directly between cells of small metabolites and water, respectively, the cytoskeletal protein beaded filament structural protein-2 (BFSP2),6 and transcription factors paired-like homeodomain transcription factor-3 (PITX3)7 and heat shock factor-4 (HSF4).8 Five additional loci have been described on chromosomes 1pter-p36.1,9 15q21-22,10 17p13,11 17q24,12 and 20p12-q12.13

We used a linkage approach to investigate these 13 genes and five loci in a large pedigree from Victoria, Australia, with zonular pulverulent cataract with the aim of identifying the causative mutation.

METHODS

Ethics approval for this study was obtained from the Human Research Ethics Committees of the Royal Children’s Hospital, Melbourne, Australia, the Royal Victorian Eye and Ear Hospital, Melbourne, Australia, and the University of Tasmania, Hobart, Australia.

Patient ascertainment and collection of genetic material

The pedigree crch13 was identified through a database maintained by the Royal Children’s Hospital, Melbourne, Australia and the Royal Victorian Eye and Ear Hospital, Melbourne, comprising paediatric cataract patients from south-eastern Australia with any type of lens opacity.14 Written informed consent was obtained from all participating individuals or their guardians. When possible, family members were examined by one or more ophthalmologists (MGW, DAM, JEE, JEC, or IR-E). Due to the rural location of most family members, affection status was determined from medical records when direct examination was not feasible. In many cases pre-operative visual acuity was not available. Buccal mucosal swabs were either collected during examination or by mailed kits and DNA extracted using the PureGene DNA Isolation Kit (Gentra Systems). Unaffected controls were ascertained from nursing homes for the elderly in Launceston, Tasmania, Australia, and were found to be free of ophthalmic disorders, including any form of cataract. Blood was collected from control individuals and DNA extracted with the Nucleon BACC3 kit (Amersham Pharmacia Biotech).

Linkage analysis

All individuals were genotyped at microsatellite markers representing known cataract genes and loci by the analysis of fluorescently-tagged PCR products on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). Two-point LOD scores were calculated using the FASTLINK package.15 Allele frequencies were obtained from the population control samples. Penetrance was set at 0.95 in heterozygotes and homozygous variants. Disease gene frequency was set to 0.0001.

Sequencing

The coding region of CX46 was sequenced using three overlapping PCR fragments. Primer sequences were: 1F: 5’-CGGTGTTCATGAGCAATTTC-3’, 1R: 5’-GAAGTAGGCCCCGAGC-3’, 2F: 5’-GGGAGAATCCTCGTC-3’, 2R: 5’-GGTACGGGCTGAGCAGTTGA-3’, 3F: 5’-GGGAGAATCCTCGTC-3’, 3R: 5’-GGGAGAATCCTCGTC-3’, PCR products were cycle sequenced with Big Dye Terminator Ready Reaction Mix (Applied Biosystems) and analysed on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems).

Computational methods

ClustalW® (http://www.ebi.ac.uk/clustalw/) was used to align CX46 protein sequences from five mammalian species represented in GenBank. The likely structure of the CX46 protein was determined using HMMTOP17 18 (http://www.enzim.hu/hmmtop/index.html) and MEMSAT from the PSIPRED server19 20 (http://bioinf.cs.ucl.ac.uk/psipred/).

Key points

- Congenital or paediatric cataract is a highly heterogeneous disorder with 13 known genes and at least five additional loci identified.
- A linkage approach was used to investigate a large pedigree from south-eastern Australia with a faint lamellar opacity surrounding a nuclear pulverulent cataract, with occasional fine needle-like cortical riders.
- Linkage to the Connexin46 locus was identified.
- An R76H mutation was identified in all affected individuals and not found in 100 control chromosomes.
- The mutation was also identified in six unaffected carriers, indicating reduced penetrance of the mutation.

Abbreviations: ADCC, autosomal dominant congenital cataract; BFSP2, beaded filament structural protein-2; HSF4, heat shock factor-4; MIP, major intrinsic protein; PITX3, paired-like homeodomain transcription factor-3
RESULTS

The phenotype in this pedigree is a faint lamellar nuclear opacity surrounding pulverulent nuclear opacities (Fig 1), some with fine gold dots or haze and some with needle-like peripheral riders. The median age of diagnosis was 5 years (range 0–73 years), however the 10 patients in the two most recent generations (generations VI and VII) were diagnosed at 6 months to 2 years. Of 42 eyes with cataracts, 20 had not had surgery and have good or minimally (6/9) reduced vision. The median age of surgery was 17–26 years (range 10–67 years). No other systemic or ocular abnormalities, such as nystagmus, strabismus, or iris abnormalities, were noted. One older female diagnosed at age 5 years and operated on at age 67 years, developed pseudophakic glaucoma.

A LOD score of 2.96 was obtained at \( \theta = 0.04 \) from D13S1236, the marker included to detect linkage to the \( \text{CX46} \) gene. Other candidate loci implicated in ADCC (\( \text{CX50}, \text{CRYGD/GC, CRYBA1} \), \( \text{1pter-p36.1, 15q21-q22, 17p13, 17q24} \)) were excluded by linkage analysis (data not shown). An equivocal LOD score of 1.36 at \( \theta = 0.08 \) from marker D16S496 representing \( \text{HSF}4 \) was the only other positive LOD score. Once the significant result at D13S1236 was obtained, additional ADCC loci (\( \text{BFSP2}, \text{PITX3}, \text{CRYAB}, \text{MIP}, \text{CRYAA}, \text{CRYBB2} \), and \( \text{20p12-q12} \)) were not investigated for this monogenic disorder.

\( \text{CX46} \) was sequenced in affected individuals and the variant 226G>A (GenBank reference NM_021954) causing an R76H substitution was identified in all 21 affected individuals but not in 100 control chromosomes by direct sequencing. Six unaffected relatives (IV:4, V:7, V:8, V:9, V:27, and V:15) were also found to carry the mutation (Fig 2). This residue is conserved across species represented in GenBank (Fig 3). The residue is predicted by MEMSAT to be at the boundary between extracellular loop 1 and transmembrane loop 2 while HMMTOP predicts that it is within the second transmembrane domain.

DISCUSSION

The investigation of this large Australian cataract pedigree has revealed a novel mutation, R76H, in the \( \text{CX46} \) gene. The R76H mutation is likely to be causative as it segregates with affected status amongst reasonably distant branches of the pedigree with the same phenotype and was not detected in unaffected, unrelated controls. The inheritance in this pedigree is clearly autosomal dominant, although not fully penetrant.

Connexin proteins form hexamers known as connexons in the cell membranes. Connexons in neighbouring cells dock to form gap junctions which allow the transport of small metabolites directly between cells. Two connexins, \( \text{CX46} \) and \( \text{CX50} \), are expressed in lens fibre cells. Previously reported mutations of these genes associated with congenital cataracts

---

**Figure 1** A range of pulverulent cataract phenotypes of pedigree crch13. (A) Mild pulverulent phenotype of the nucleus of individual VI:8, directly illuminated and (B) retroilluminated. (C) Mild pulverulent phenotype of the nucleus with a cortical lamella opacity of individual VII:2, directly illuminated and (D) retroilluminated. (E) Mild pulverulent phenotype in the nucleus with cortical riders of individual VI:3, directly illuminated.

**Figure 2** Pedigree diagram of crch13 indicating the presence of Connexin46 R76H mutation. Shaded symbols indicate the presence of an ophthalmologist-confirmed cataract. Squares indicate males, circles females, “+” heterozygote, and “−” wild type. Individuals with no “+” or “−” symbol have not been typed.
are shown in table 1. All seven mutations have been linked to zonular pulverulent congenital cataracts which are “pulverised” dust-like or punctate opacities in developmental zones of the lens. The phenotype in the Australian pedigree in the present study resembles those previously reported. All mutations of connexin genes described previously appear fully penetrant in the pedigrees in which they were detected.

The R76 residue of CX46 is conserved between species (fig 3), indicating that the arginine is likely to be functionally important and that the mutation may therefore have a detrimental physiological effect. It is not clear whether R76 is located in the first extracellular loop or in the second transmembrane domain. Other cataract mutations have been detected in both these domains (table 1). Mutations in the extracellular domains may affect connexon docking if the conformation of the loop is changed. It is unclear what the affect of variation within the transmembrane domain would be, however, other mutations of transmembrane domains of connexin genes have been reported. The wild type arginine has a positive charge while histidine can be either positively charged or neutral, depending on the microenvironment. This may help explain the incomplete penetrance observed if cataract formation is dependant on the ionisation of this residue.

A lack of gross effects on protein structure is implied by both the range of ages at which surgery was performed, indicating a phenotype of variable severity, and the incomplete penetrance observed in the pedigree. Individuals V:27 and VI:15 have been examined by several of the investigators and are clearly unaffected. Carrier individuals IV:1, V:7, VIII:5, VIII:6, V:9 have not been examined by a member of our research group and, therefore, it is possible that they may be subtly affected. The only other report of a monogenic paediatric cataract mutation with incomplete penetrance is a 5 bp insertion in the γ-crystallin gene causing a variable zonular pulverulent phenotype.22 The variability was suggested to be due to environmental factors or modifying genes. Unaffected individuals IV:4 and V:27 have passed on the R76H mutation to their offspring, who also remain unaffected. Environmental factors are unlikely to show this type of pattern, unless there are significant household effects, suggesting the possibility of a second modifying or protective gene.

Investigations of animal models may help elucidate the nature of modifying genes. Mice with a disrupted cx46 gene develop a nuclear lens cataract. The cataract phenotype and presence of cleaved γ-crystallin in the lens was variable, depending on the genetic background of the mouse, indicating the presence of modifier genes involved in the development of the phenotype.23 The Lop10 mutation in mice may also provide some insight. This phenotype is caused by the G22R variant of murine cx50,24 however, the phenotype is variable and dependent on the genetic background of the mouse.25 These examples provide evidence for modifier genes in the development of congenital cataract and support the hypothesis of modifier genes acting in the pedigree described here.

In summary, a novel mutation of the human CX46 gene has been found to segregate with a pulverulent phenotype. The mutation is only the second reported congenital cataract mutation with incomplete penetrance in the literature and, as such, provides an opportunity for the investigation of modifying genes and their interactions.

**ACKNOWLEDGEMENTS**

We wish to thank the family for their participation. Thanks are also due to Susan Stanwix, Mimiwati Zahari, and Danielle Healy for assistance in arranging ophthalmic examinations and DNA collection and Andrew Bell and Michelle Brown for technical assistance.

**Authors’ affiliations**

K P Burdon, J L Dickinson, M M Sale, Menzies Centre for Population Health Research, University of Tasmania, Hobart, Australia
K P Burdon, M M Sale, Center for Human Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA
K P Burdon, Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC, USA
K P Burdon, Department of Ophthalmology, Flinders University, Bedford Park, Australia
K P Burdon, J E Craig, K P Burdon, M M Sale, Great Ormond St Hospital for Children, London, UK
K P Burdon, M M Sale, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA
K P Burdon, M M Sale, Department of Ophthalmology, Flinders University, Bedford Park, Australia
K P Burdon, M M Sale, Department of Ophthalmology, Flinders University, Bedford Park, Australia

Grant support for this project was received from the Ophthalmic Research Institute of Australia, the Jack Brockhoff Foundation, and the Royal Hobart Hospital Research Foundation.

Conflict of interest: none declared.

**Table 1**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Mutation</th>
<th>Location</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CX46</td>
<td>N635S</td>
<td>C-terminal cytoplasmic tail</td>
<td>McKay et al., 1999</td>
</tr>
<tr>
<td></td>
<td>N635S</td>
<td>First extracellular loop</td>
<td>McKay et al., 1999</td>
</tr>
<tr>
<td></td>
<td>P187L</td>
<td>Second extracellular loop</td>
<td>Rees et al., 2000</td>
</tr>
<tr>
<td></td>
<td>F32L</td>
<td>First transmembrane domain</td>
<td>Jiang et al., 2003</td>
</tr>
<tr>
<td></td>
<td>E48K</td>
<td>First extracellular loop</td>
<td>Berry et al., 1999</td>
</tr>
<tr>
<td></td>
<td>I427M</td>
<td>C-terminal cytoplasmic tail</td>
<td>Polyakov et al., 2001</td>
</tr>
<tr>
<td></td>
<td>P88S</td>
<td>Second transmembrane domain</td>
<td>Shiels et al., 1998</td>
</tr>
</tbody>
</table>
REFERENCES


HEREDITARY HEARING LOSS AND ITS SYNDROMES, 2ND EDN


Although formally classified as the second edition, this is essentially the third version of the groundbreaking book by Bruce Konigsmark and Bob Gorlin entitled Genetic and Metabolic Deafness as originally published in 1976. Subsequent recognition of the pressing need to incorporate the rapid expansion in knowledge of new syndromes prompted the appearance of the first edition of Hereditary Hearing Loss and its Syndromes in 1995, as a sister publication to Syndromes of the Head and Neck. This new edition represents the coming of age of the marriage between molecular biology and conventional clinical genetics and provides an excellent state of the art synthesis of contemporary knowledge.

A reviewer’s task in making criticism of an outstanding and definitive textbook is not an easy one. In planning this new edition the editors have resisted the temptation to tinker with a successful format to the extent that the overall structure is virtually unchanged. The existing chapter on endocrine and metabolic disorders has been split into two and the miscellaneous chapter has disappeared, to be replaced by a chapter on cardiac syndromes. Otherwise the chapter headings are as in the previous edition with much of their text reproduced, albeit with expanded sections on “heredity” to embrace the many new discoveries of the last few years. Thus the contents can be subdivided into four introductory chapters which set the scene, followed by 12 chapters describing the genetic and biochemical aspects of hearing loss syndromes. In general these are excellent, with each providing detailed accounts of an exhaustive list of common and rare conditions in which hearing loss can occur. All these are lavishly illustrated with ample references for those who wish to delve further.

Against this background of general excellence any possible hint of criticism might well be viewed as petty and inappropriate, so it is hoped that the editors will overlook the personal comments. Most readers will be very familiar with the basic principles of human genetics so that on turning to the chapter on genetic counselling it was disappointing to find that this is largely limited to an explanation of traditional patterns of inheritance. The real challenge facing most clinical geneticists and genetic counsellors is how to counsel the hearing parents of a child with an isolated non-syndromal hearing loss. Chapter 2 provides useful suggestions for investigation but the subsequent chapter on genetic counselling provides little in the way of assistance. True, there is a useful table (of unstated source) providing empirical risks, but with little in the way of guidance as to how these should be applied. Should these risks be modified on the basis of age of onset, laterality, asymmetry, progression, vestibular involvement, audiology or a normal Connexin 26/30 mutation analysis? Presumably they should, but how? The editors and chapter authors embrace most of the world’s experts on genetic hearing loss and it is a little unfortunate that they could not expand on this crucial component of the counselling process. An overview of how genes and their products interact to facilitate the hearing process would also be useful, as would expansion of some of the sections on molecular pathogenesis in the system orientated chapters. Finally, the era when medical books can include full frontal nude photographs of children and adults must be coming to a close and one wonders how many of the stark naked adults appearing in some of the syndrome chapters gave informed consent for their publication in perpetuity.

Clearly these are minor criticisms of an excellent textbook which will provide an invaluable resource and be consulted widely. It is difficult to see how any department encountering patients with hearing loss could possibly manage without it.

I Young

BOOK REVIEW

CORRECTIONS

doi: 10.1136/jmg.2005.18333corr1
An error has been detected in the online mutation report by Burdon et al (J Med Genet 2004;41:e106). The mutation is identified in the manuscript as 226G>A in regards to the Genbank reference NM_021954. However, it should be 227G>A. The amino acid designation, R76H, is correct and this numbering error does not change any of the other results or conclusions of the article. The author apologises for this error.

doi: 10.1136/jmg.2004.013151corr1
Several errors have been detected in the electronic letter by Toyama et al (J Med Genet 2004;41:e74). First, the abbreviations for Table 1 should read:

Ex, exon; (FAM)-,FAM-labelled; (HEX)-, HEX-labelled; (ROX)-,ROX-labelled; (NED)-, NED-labelled; UP, upstream; Pro, promoter; Int, intron; Fl, flanking; STR, short tandem repeat.

Second, the parenthesised section of the last sentence of the Results should read:

(7.3 ± 1.0 mmol/l) and 7.63 ± 1.0 mmol/l (M310I) compared to that of the wild type (3.8 ± 0.4 mmol/l).

In addition, in Ex4 of Table 3 the “Type” should read C235 (R79W), in Figure 1 “European Am” is the abbreviation for “European American,” and in Table 4 the title should read “Catalytic activity of recombinant AMPD1 expressed in E. coli”.

We apologise for these errors.

doi: 10.1136/jmg.2004.019190corr1
The authors for the paper titled Positive association of the DIO2 (deiodinase type 2) gene with mental retardation in the iodine-deficient areas of china (J Med Genet 2004;41:585–590) have identified an error within their abstract. The second line from the results section should read: Particularly with rs255012, CC genotype frequency was significantly higher in MR cases than in controls (chi squared = 9.18, p = 0.00246). The author apologises for this mistake.
SOX9, comprising 8% of mutations in campomelic dysplasia), the finding of the same point mutation in >2 unrelated infertile men is a strong indication that the mutation has no dominant deleterious effect, and extensive population screening is required to show otherwise.


REFERENCES

CORRECTION
doi:10.1136/jmg.2004.018333corr1

Burdon KP, Wirth MG, Mackey DA, Russell-Eggitt IM, Craig JE, Elder JE, Dickinson JL, Sale MM. A novel mutation in the Connexin 46 gene causes autosomal dominant congenital cataract with incomplete penetrance. J Med Genet. 2004;41:e106. The authors apologise for an error in figure 2. Individuals V:1 and IV:12 should be marked as affected. Both have ophthalmologist confirmed cataract. The corrected Figure 2 is shown here.